# Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

> **NCT00409942** · PHASE4 · COMPLETED · sponsor: **Ferrer Internacional S.A.** · enrollment: 142 (actual)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **DRUG:** Torasemide Prolonged Release
- **DRUG:** Furosemide

## Key facts

- **NCT ID:** NCT00409942
- **Lead sponsor:** Ferrer Internacional S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2009-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409942, "Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00409942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*